Aspiration & Biopsy Needles Market

Aspiration & Biopsy Needles Market Analysis

The Aspiration & Biopsy Needles Market size is estimated at USD 1.18 billion in 2025, and is expected to reach USD 1.66 billion by 2030, at a CAGR of 7.15% during the forecast period (2025-2030).

• The rising incidence of cancer, awareness about the disease and treatment options, patient preference for minimally invasive surgeries, rising healthcare spending, and technological advancements in image-guided biopsy systems are all driving the market forward.
• According to an article published in the Chinese Medical Journal in February 2022, an estimated 4,820,000 new cancer cases were expected in China and 2,370,000 in the United States in 2022. The most common cancers were lung cancer in China and breast cancer in the United States. The rising incidence and mortality of cancers such as breast cancer led to higher adoption of needle-based biopsy instruments for testing breast cancer, thereby indicating this market's high growth.
• Additionally, governments of different countries are taking initiatives to increase awareness about cancer and its diagnosis so that it can be detected earlier. For instance, in February 2022, the Health Minister of Tamil Nadu, a state of India, stated that the Government of Tamil Nadu is engaged in framing a policy to identify 66% of cancer patients in the first and second stages by 2030 and thus proper treatment could be availed. Hence, such policies are expected to drive the growth of the market, as it would increase the usage of biopsy needles for cancer diagnosis.
• Moreover, the market is expected to be driven by technological advancements, product launches, and merger and acquisition activity by key market players during the forecast period. For instance, in August 2022, Mammotome unveiled its groundbreaking Mammotome DualCore biopsy system, marking its debut in the dual-stage core biopsy instrument market. With its lightweight, ergonomic, and intelligent design, the device minimizes needle movements and vibrations and enhances the overall patient experience.
• Thus, the factors mentioned above are expected to drive market growth during the forecast period. However, the market is constrained by the risk of infections associated with aspiration and biopsy needles.

Aspiration & Biopsy Needles Market Trends

The Breast Cancer Segment is Expected to Experience Significant Growth During the Forecast Period

• In recent years, the prevalence of breast cancer has increased significantly worldwide, driving the demand for better and more accurate treatment procedures, which is expected to drive the segment's growth. For instance, according to the data updated by Cancer Australia in January 2023, it was estimated that 20,640 new cancer cases will be diagnosed in Australia in 2022, accounting for 12.7% of the new cancer cases diagnosed in the country. The source also stated that breast cancer will be the second most commonly diagnosed cancer in 2022 in Australia. Thus, the rising prevalence of breast cancer will increase the demand for breast biopsies, which, in turn, will drive the demand for aspiration and biopsy needles, thereby boosting segment growth.
• The awareness campaign organized by the Ministry of Health of various countries also raises awareness about cancer, thus boosting the segment's growth. For instance, according to the data published by the South African Government in October 2022, the incidence of breast cancer among South African women is said to be increasing, and it is one of the most common cancers among women in South Africa. It is one of the most prevalent cancers among white and Asian women in South Africa and the second most common cancer among black and colored women.
• The government also stated that the early detection of the condition can lead to effective treatment and a positive prognosis, and it is estimated that about 90% of patients survive many years after diagnosis when breast cancer is detected at the early stages. Such initiatives taken by governments to educate about cancer will lead to early diagnosis of cancer and thus drive the segment's growth.
• Moreover, in February 2022, the American Hospital of Paris officially launched its One-Day Breast Diagnosis, a personalized care pathway for women with suspected breast cancer following the detection of a clinical anomaly or an abnormal imaging result. The procedure includes a consultation with an oncologist specializing in breast cancer and a radiological workup and fine-needle aspiration, the results of which are available within a half-day. Such initiatives undertaken by hospitals are also expected to contribute to the growth of the segment.
• Thus, owing to the above-mentioned factors, the breast cancer segment is anticipated to grow during the forecast period.

North America is Expected to Hold a Significant Share of the Market During the Forecast Period

• North America is expected to hold a significant share of the market due to the growing prevalence of cancers, rising awareness about early cancer detection, high healthcare spending, and the increasing number of device approvals by the United States Food and Drug Administration.
• According to the data published by the American Cancer Society in 2024, an estimated 288,010 new prostate cancer cases will be identified in the United States in 2024. In addition, according to the same source, about 6 cases in 10 are diagnosed in men aged 65 or older. Such an increase in the prevalence of cancer is estimated to boost the demand for aspiration and biopsy needles for early diagnosis, ultimately driving the market's growth in the region.
• Additionally, according to the data stated by the Canadian Cancer Society in November 2023, it was estimated that 233,900 people will be diagnosed with cancer in 2022, and this growth in incidence is largely due to Canada's growing and aging population. Thus, the growing prevalence of cancer is expected to boost the usage of aspiration and biopsy needles, thus driving the growth of the market in the region during the forecast period.
• Moreover, market players in North America focus on growth strategies such as new product launches, partnerships, mergers, and acquisitions. For instance, in November 2022, Cambridge Enterprise introduced the Cambridge Prostate Biopsy Device (CamPROBE) to reduce the infection risk associated with conventional transrectal biopsies. This innovative device features an integrated needle for localized anesthesia delivery.
• Also, the strong foothold of key players in the United States is further expected to drive the growth of the aspiration and biopsy needles market in this region. Key market players such as Danaher, Beckton Dickinson, Hologic, Cook Medical, and Boston Scientific launched their products in the United States, leading to higher adoption of these devices in this region.
• Thus, all the aforementioned factors are expected to drive market growth in North America during the forecast period.

Aspiration & Biopsy Needles Industry Overview

The aspiration and biopsy needle market is fragmented due to many market players and their increasing product launches. These companies are undertaking strategies, such as product launches through technological innovations and partnerships, to gain profits in the industry. Thus, new product launches are the most preferred strategy, followed by collaborations and geographical expansion for market capitalization. The major market players operating in the aspiration and biopsy needle devices market are Olympus Corporation, Cardinal Health, Conmed Corporation, and Medtronic Inc.

Aspiration & Biopsy Needles Market Leaders

Aspiration & Biopsy Needles Market News

• May 2024: Cook Medical introduced its latest iteration of the EchoTip AcuCore Endoscopic Ultrasound (EUS) Biopsy Needle in the United States
• August 2022: Mammotome unveiled its groundbreaking Mammotome DualCore biopsy system, marking its debut in the dual-stage core biopsy instrument market. With its lightweight, ergonomic, and intelligent design, the device minimizes needle movements and vibrations and enhances the overall patient experience.